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Acquired factor VIII deﬁciency is a bleeding disorder caused by the presence of autoantibodies against clotting factor VIII. We
report a case of a 24-year-old pregnant woman who presented with gross hematuria secondary to acquired factor VIII deﬁciency
in the presence of a previously undiagnosed connective tissue disease. This article includes a literature review of pregnancy-related
cases of acquired factor VIII deﬁciency. We also reviewed various therapeutic approaches for the management of the acquired
factor inhibitor which include achieving hemostasis and elimination of the inhibitor via immunosuppressive agents. This case
report describes the rare presentation of acquired factor VIII deﬁciency related to pregnancy and highlights the importance of
considering a factor VIII inhibitor in the diﬀerential diagnosis of patients who present with bleeding and prolonged PTT during
the peripartum and postpartum periods.

1. Introduction

2. Case Presentation

Acquired factor VIII deﬁciency is a rare bleeding diathesis
caused by the development of autoantibodies against clotting
factor VIII [1]. The annual incidence of the disorder is between
1.3 and 1.5 per million [1]. Apart from reproductive-aged
women during pregnancy and postpartum periods, acquired
factor VIII deﬁciency typically occurs after the ﬁfth decade of
life [2]. Patients aﬀected with acquired factor VIII deﬁciency
present with severe or life-threatening bleeding episodes in the
absence of previous bleeding predisposition. Bleeding severity
varies ranging from simple dermatological manifestations such
as petechiae and ecchymoses to internal bleeding [3] Acquired
factor VIII deﬁciency has been associated with several underlying conditions such as malignancy, immunological disorders, perinatal period, and various medications. Although the
association with underlying disorders has been reported, most
of the cases remain idiopathic.

A 24-year-old Hispanic pregnant woman, gravida 2 para 1,
was admitted for gross hematuria without precipitating
factors at 29 weeks of gestation. The patient reported that
this was the ﬁrst episode of hematuria and had no prior
history of bleeding during her previous pregnancy or otherwise. The patient’s review of systems was signiﬁcant for an
erythematous, maculopapular, nonpruritic rash, occurring
intermittently on the lower extremities since age 13. The
patient had never been given a formal diagnosis but noted
that the rash also occurred during her ﬁrst pregnancy, resolved spontaneously, and recurred about 2 weeks prior to
the current admission. The patient denied family history of
hemophilia, von Willebrand disease, or autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or Hashimoto’s thyroiditis. The
patient endorsed episodes of photosensitivity but denied
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constitutional symptoms, arthralgia, oral ulcers, myalgia,
pleuritic chest pain, xerostomia, keratoconjunctivitis sicca,
or any other signiﬁcant symptoms. On physical examination, the patient had bilateral upper extremity and lower
back large ecchymoses, a palpable purpura on the anterior
aspect of the right thigh, bilateral knees, and hips, and
postinﬂammatory hyperpigmentation on the distal aspect of
lower extremities. Laboratory tests (Table 1) showed a
prolonged PTT of 92.1 s (RI: 24.3–36.7 s). Subsequent
workup revealed negative antiphospholipid panel including
negative pus anticoagulant, cardiolipin antibodies, and beta2 glycoprotein 1 antibodies. The von Willebrand factor was
present in adequate amounts. There was a signiﬁcantly
decreased factor VIII level of <1% (RI: 50–180%), and PTT
failed to correct with the addition of fresh plasma (mixing
studies) which suggested the presence of an inhibitor.
Bethesda assay was positive at 74.9 U (RI: 0.6 U) which
conﬁrmed a high titer factor VIII inhibitor. Further workup
revealed a positive antinuclear antibody with high titer by
ELISA and positive SS-A and SS-B antibodies. Urinalysis
showed proteinuria of 858 mg/24 h. Double-stranded DNA
and anti-Smith antibodies were negative. Complement C3
and C4 were present in normal amounts. The patient was
diagnosed with acquired factor VIII deﬁciency and presumed systemic lupus erythematosus (SLE). She was initially
treated with DDAVP 30 mcg intranasally along with prednisone 45 mg BID (1 mg/kg a day in divided doses) while in
our facility. The patient was transferred to a tertiary center
for a higher level of care where she received IVIG (intravenous immune globulin) 1 gm/kg for 2 days along with
porcine factor VIII. She was discharged from the hospital on
a prednisone taper. The patient was followed closely by a
maternal-fetal medicine specialist and a hemophilia specialist. The patient later delivered a healthy baby girl at 36
weeks via vaginal delivery without complications. At the
three-year follow-up, the patient remains in remission, and
her daughter has been without any cardiac problems or
bleeding diathesis. She was advised against future pregnancy.

3. Discussion
Acquired factor VIII deﬁciency associated with pregnancy
most commonly occurs during the peripartum and postpartum period and rarely occurs before pregnancy. The
cause and timing remain unclear, but many studies speculate
that it is due to the complex immunological changes that
occur during pregnancy. Some sources have theorized that
the development of the inhibitor is due to sensitization of the
mother’s immune system to fetal factor VIII during previous
pregnancies; however, some patients who acquire an inhibitor to factor VIII develop the inhibitor in the ﬁrst
pregnancy (Table 2). The inhibitor autoantibody that is
produced in patients with acquired factor VIII deﬁciency
attaches to a speciﬁc subunit of factor VIII, the C2 domain,
which results in diminished procoagulant activity and
subsequent bleeding [16]. This is like the formation of
neutralizing antibodies against factor VIII in 25% of patients
with hemophilia A who are transfused with plasma-derived
or recombinant factor VIII. In the rare event of clinical
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Table 1: Laboratory results.
Parameter
PT
INR
PTT
Coagulation factor VIII activity
Factor VIII inhibitor titer
vWF Ag
vWF ristocetin cofactor
vWF Ag, multimeric
PTT-La screen
Hexagonal phase conﬁrm
DRVVT screen
DNA ds Ab
RNP 70
Rheumatoid factor quantitative
ANA
Cardiolipin Ab IgG
Cardiolipin Ab IgM
B2-glycoprotein IgM Ab
B2-glycoprotein IgG Ab
Anticentromere antibody
Jo 1 antibody
Scl 70 antibody
Smith antibody (Sm)
SS-A/Ro antibody
SS-B/La antibody
U1RNP antibody
Complement C3
Complement C4
Immunoglobulin A
Antistreptolysin O
ANCA
Urine culture
Random urine protein/creatinine
ratio

Patient

Reference
range
9.8–12.6 s
0.87–1.15
24.3–36.7 s
50–180%
<0.6 BU
50–217%
42–200%

11.8 s
1.05
92.1 s
<1%
74.9 BU
190%
122%
Normal
80 s
<40 s
Negative
22 s
<45 s
0.9 IU/mL
<10 IU/mL
0.3 U/mL
<7.0 U/mL
44.6 IU/
<14.0 IU/mL
mL
>32.0 ratio
>1.0 ratio
<14 GPL
< or � 14
<12 GPL
< or � 14
<9 GPL
< or � 20
<9 GPL
< or � 20
<0.4 U/mL
<7.0 U/mL
<0/3 U/
<7.0 U/mL
mL
<0.6 U/mL
<7.0 U/mL
<0.8 U/mL
<7.0 U/mL
>240 U/
<7.0 U/mL
mL
97 U/mL
<7.0 U/mL
0.6 U/mL
<7.0 U/mL
174 mg/dL 87–200 mg/dL
20 mg/dL 19–52 mg/dL
242 mg/dL 66–443 mg/dL
<1 IU/mL
<250 IU/mL
Negative
Negative
858 mg/
161 mg/gm
gm

manifestations during pregnancy, such as in our patient, the
presence of factor VIII autoantibodies also puts the fetus at
risk of bleeding due to the maternofetal transplacental
passage of IgG antibodies. To date, there are less than ﬁfty
reported cases of the maternal transplacental passage of the
inhibitor resulting in acquired factor VIII deﬁciency in the
fetus. Although rare, it is important to counsel the patient on
the possibility of these risks [17]. There is no current accurate
way to determine the severity of bleeding in patients with
factor inhibitors based solely on titer levels. Studies have
shown that inhibitors to factor VIII are cleared in a nonlinear manner, thus resulting in an underestimation of
bleeding risk in some patients [18].
Acquired factor VIII deﬁciency occurs most commonly
in primigravid women at 2-3 months postpartum. These
patients typically present with soft tissue bleeding; however,
vaginal bleeding, hemarthrosis, and hematuria have been the
presenting symptoms in 13–18% of the reported cases [3].
Although our patient was gravida 2, she delivered her ﬁrst
child 2.5 months prior to the conception that resulted in her
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Table 2: Review of the literature.

Article

Citation

Presentation
37 y/o G1P1 presented 4 months
postpartum with bruises and hemarthrosis.
22 y/o G3P3 presented 7 months
postpartum with menorrhagia and
bleeding after tooth extraction.

41

Michiels
et al. [4]

31 y/o G2P2 presented 2 months
postpartum with muscle and soft tissue
bleeding, menorrhagia, ecchymoses, and
hemarthrosis.

24 y/o G2P1A1 presented after delivery of
stillborn with PPH and subsequent
hemarthrosis.

38

Coller et al. 22 y/o primigravid woman presented with
[5]
severe vaginal bleeding postpartum day 6.

6

Chaari et al.
[9]

19 y/o F presented PPD one with large
vaginal hematoma.

5

Seethala
et al. [7]

36 y/o woman presented with PPH s/p
NSVD secondary to acquired factor VIII
deﬁciency.

4

31 y/o G1P1p developed postpartum
hemorrhage after delivery.
Kotani et al. A female neonate developed subcutaneous
[8]
hemorrhage on dorsum of hand on day 1of
life s/p routine blood draw secondary to
transplacental transfer of the inhibitor.

Findings
FVIII-0.02 U/mL
FVIII inhibitor:
7.9 BU

Outcome
Treated with prednisone taper of 1 mg/kg
with remission within 2 months while on
20 mg/d without recurrence at 5-year f/u.
Treatment with cyclophosphamide 100 mg/
day (0.7 mg/kg/d) without inhibitor
FVIII: 0.01–0.02 U/
disappearance; however, spontaneous
mL
remission developed 10 months later after
FVIII inhibitor: 12 BU
discontinuing medication. Subsequent
pregnancy without bleeding diathesis.
Treated with 4000 U human factor VIII,
prednisone 1 mg/kg/d for 6 weeks, and
cyclophosphamide 2 mg/kg/d concomitantly
from the 3rd to 6th week of prednisone
FVIII: <0.01 U/mL
treatment, with a 5-day course of high-dose
FVIII inhibitor: 24 BU
gamma-globulin at 0.5 g/kg/day. Recurrence
of the inhibitor with removal of agents
resulting in IVIG being initiated. Remission
at 28 months.
Treated with 1 mg/kg prednisone for 3 weeks
FVIII: <0.01
without remission. Five years later presented
FVIII inhibitor:
with FVIII 600 BU and thus 10K U of
295–625 BU
cryoprecipitate. At 24 years after treatment,
the patient still had not achieved remission.
PT: 12.6/13.0 sec
PTT: 74/45 sec
Treated with 60 mg prednisone daily, became
FVIII: 8%
free of inhibitor within months, and had a
FIX: 90%
successful second pregnancy without any
FVIII inhibitor: 15 BU
subsequent bleeding diathesis.
von Willebrand factor:
90%
Treatment began with initial surgical
intervention for evacuation of hematoma but
was complicated by bleeding into the
abdominal cavity and genitalia. The patient
was given recombinant FVIIa and activated
aPTT: 87/30 sec
prothrombin complex concentrates. Due to
FVIII: 7%
FVIII inhibitor: 64 BU symptom progression, the patient started on
prednisone alone for 3 days followed by
cotherapy with cyclophosphamide without
symptom improvement. The patient passed
away PPD 2/2 hemorrhagic shock.
Received factor VII and desmopressin.
PTT: 71.7/45 sec
Treated with methylprednisolone, cytoxan,
PT: 15.9 sec
and plasmapheresis with appropriate decline
INR: 1.3
in PTT but was discontinued because of sepsis
FVIII: <1%
prior to discharge. The patient was readmitted
FVIII inhibitor:
for bacteremia and succumbed to severe
>54.3 BU
sepsis.
PT: 10.6 sec
Treatment for 31 y/o F consisted of 19 U
PTT: 76.9 sec
PRBCS, 51 U FFP, steroid pulse therapy, and
FVIII: <1%
3 vials of factor VII during hospital course
FVIII inhibitor:
and discharged on 30 mg/day of
458 BU/mL
prednisolone. 10 months postpartum PTT
PT: 14.3 sec
WNL without any further complications.
PTT: 80.3 sec
Neonate required no treatment and factor
FVIII: <1%
VIII, and PTT returned to baseline at
FVIII inhibitor:
postnatal month 4.
199 BU/mL

4
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Table 2: Continued.

Article
35

8

23

7

Citation

Presentation
31 y/o woman presented with several areas
Chaari et al.
of ecchymoses over lower extremities
[6]
several days prior to delivery.

Porteous
et al. [10]

32 y/o primigravid woman developed
postpartum hemorrhage hours after
delivery.

Sebastian
et al. [11]

25 y/o F with a history of secondary APS in
the setting of SLE and acquired factor VII
inhibitor at 10 weeks of gestation
developed retroperitoneal bleeding. Prior
to current conception, the patient was
symptomatic having suﬀered from several
areas of ecchymoses on extremities,
episcleritis, and urticaria and having been
diagnosed with a PE 6 months prior.

Rodrigues
et al. [12]

34 y/o primigravid F presented PPD forty
with complaints of spontaneous
hematomas on extremities and
intramuscular bleeding on the back,
forearms, ankle, and thighs.

29

18 y/o F primigravid presented 9 months
postpartum with painful swelling of knees
Lee et al. [13]
and ankles, multiple bruises on hands and
feet, and menorrhagia.

39

Azam et al.
[14]

26-year-old multiparous woman presented
PPD 2 with hemoperitoneum following
lower segment C-section.

2

Qian et al.
[15]

35-year-old PPD 48 with chest pain and
was found to have pleural hemorrhage.

current pregnancy. As the immunology of pregnancy poses a
conundrum, the presence of an untreated autoimmune
condition could have potentially interfered in the dynamic of
antibody formation and clearance in our patient.
The isolated elevated PTT that failed to correct with the
mixing study in the context of bleeding is suggestive of the
inhibitor rather than lupus anticoagulant with latter triggering clotting events. Laboratory testing was negative for
the lupus anticoagulant, but factor VIII activity was

Findings
FVIII: 18%
FVIII inhibitor: 1,
4 BU

Outcome
Treated with prednisone and rituximab.

Treated with 1 mg/kg/day (60 mg)
prednisolone, 5 doses of recombinant FVIIa
360 IU, 2 doses of DDAVP 0.3 µg/kg, 20 U
PTT: 78.2 sec
PRBCs, tranexamic acid 1 g daily over 20 days
PT: 10.9 sec
with continued bleeding. Bleeding was
FVIII: <1%
controlled with bilateral internal pudendal
FVIII inhibitor: 15 BU
artery embolization. Maintenance therapy
was achieved with prednisolone 60 mg and
tranexamic acid 500 mg tds.
PTT: 94/37 sec
FVIII: 1.33%
Treatment consisted of methylprednisolone
FVIII inhibitor:
IV, recombinant factor VII, prednisone 1 mg/
614.4 BU
kg, and cyclosporine 250 mg/day. The patient
C3: 0.57
consented to terminate pregnancy.
C4: <0.08
Continued maintenance therapy with
Anti-ANA: 1 : 320
cyclosporine 200 mg/day, chloroquine
SS-A and Ro52:
250 mg/day, and methylprednisolone.
present
Anti-dsDNA: 18.35/
100 IU/mL
APTT: 62/<38 sec
Treated with prednisone 1 mg/kg/d plus
FVIII: 3.5%
tranexamic acid. The patient had remission of
FVIII inhibitor: 10 BU
the disease with normalization of FVIII
FIX: 124%
without the presence of the inhibitor in ∼2
Fibrinogen: 430/
years.
450 mg/DL
PT: 10.2/(10–14 sec) Treated with activated prothrombin complex
INR: 0.95/1.5 sec
concentrate and FEIBA anti-inhibitor
APTT: 84.3/40 sec coagulant complex at a dose of 50–100 units/
FVIII: 1.4%
kg q12 h. Corticosteroids were considered but
Anti-FVIII: 28 BU not indicated due to remission of symptoms.
PTT: 90 sec (0–32 sec)
Normal PT/INR
FVIII level: 1%
Positive inhibitor
Treated with prednisone 60 mg/day initially
Normal lupus
with taper and initiation azathioprine.
anticoagulant
Normal vWF
Normal
antiphospholipid IgM
and IgG
PT: 15.2 sec
PTT: 68.40 sec
Treated with aPCC, human factor VIII
FVIII inhibitor:
concentrates, corticosteroids, and plasma. At
positive
6 months, no recurrence.
Inhibitor: 7.4%

signiﬁcantly decreased at less than 1%. Bethesda assay was
positive at 74.9 U conﬁrming the presence of an inhibitor to
factor VIII. A unique aspect of our case was the importance
of recognizing the presentation of a previously undiagnosed
connective tissue disorder.
The patient reported intermittent erythematous rash
reminding of purpura as well as photosensitivity since age
13, without any formal evaluation or diagnosis. Additional
testing during current pregnancy showed the presence of
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positive ANA, SS-A, and SS-B antibodies in addition to
proteinuria, suggesting a diagnosis of SLE [19].
In addition to potential bleeding occurrence in the fetus,
the possible passive transplacental transfer of maternal antiSS-A and SS-B IgG antibodies incurs the risk of neonatal
lupus [20]. These presented a double risk for our patient that
could have potentially increased morbidity.
The phenomenon that resulted in developing an inhibitor
to factor VIII could represent a concerted occurrence of
undiagnosed SLE as an autoimmune situation and the short
interpregnancy interval between the patient’s prior and
current pregnancy and the hormonal changes associated. As
the development of factor VIII inhibitors typically occurs in
the 2-3 postpartum period, the patient became pregnant
around the same interval, and the ampliﬁcation of the process
leading to high-titer pathogenic antibodies could have been
caused by immunological processes of both undiagnosed SLE
and occurrence of subsequent pregnancy. Flares of SLE with
the characteristic antibody production that characterize the
disease occur frequently in the postpartum period.
The immunology of pregnancy in SLE poses a paradoxical juncture of immune tolerance required to insure the
viability of semiallogenic graft and the disturbance of the
tolerance characteristic of SLE. The most important immune
alteration is related to the function of Treg cells. The number
or the functionality of Treg cells is diminished in a disease
characterized by loss of immune tolerance such as SLE,
whereas the immune tolerance of the fetus is insured by Treg
in a normal pregnancy. Tregs’ presence is correlated with the
pregnancy outcome. Lower Tregs are associated with
pregnancy complications. Moreover, the immunological
processes of pregnancy are complicated by the confrontation
of two separate immune systems—the maternal immune
system and the fetal-placental immune system [21].

4. Literature Review
Our literature review identiﬁed ﬁfteen cases of acquired factor
VIII deﬁciency associated with pregnancy with patient’s ages
ranging between 18 and 37 years. The literature indicates that
most cases of acquired factor VIII inhibitors develop after the
ﬁrst pregnancy and typically between 2 and 3 months
postpartum. Based on our literature review, we did note that
several of the patients developed acquired factor VIII inhibitors after delivering their ﬁrst child; however, most patients developed postpartum hemorrhage within days of
delivery [5, 7–10]. There were other primigravid cases where
the patient developed acquired factor VIII inhibitors, but
symptoms did not manifest until 2–9 months postpartum
[4, 12, 15, 22]. Still, there were cases of acquired factor VIII
deﬁciency in women after their second pregnancy [14, 17] and
third pregnancy [4]. There did not seem to be any correlation
with the gravid status of the patient and clinical outcomes. Of
the ﬁfteen cases reviewed, two patients died from complications related directly to the acquired factor deﬁciency in the
setting of hemorrhagic shock [9] and indirectly secondary to
sepsis in the setting of immunosuppression for eradication
therapy [20]. These two women were aged 19 and 36, respectively, without other comorbid conditions and had initial
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inhibitor levels within the 50–60 BU range. An important
aspect of each of the aforementioned cases is that each patient
had signiﬁcant vaginal bleeding on presentation. In the
former case, the patient presented with a large vaginal hematoma with intra-abdominal bleeding, and the latter developed uncontrolled vaginal bleeding for which she delayed
treatment for due to travel between the United States and
Mexico. It is unclear whether the prompt intervention could
have improved outcomes in these patients, but it is important
to consider the acquired factor VIII inhibitor as a diﬀerential
in a patient with persistent vaginal bleeding during or after
pregnancy. Of note, there were three patients (including our
case) who developed an acquired factor deﬁciency prior to
delivery [6, 11]. As mentioned previously, our patient developed the inhibitor during her second pregnancy. However,
she had a short interval between her ﬁrst and second pregnancy. One of the cases of acquired factor deﬁciency prior to
delivery was in a patient with an underlying diagnosis of SLE
[11]. During our literature search, we did not identify other
cases reported of concomitant acquired factor deﬁciency in
pregnant patients with underlying connective tissue diseases.
As noted, our patient had an eventful delivery; however, the
aforementioned patient had to terminate the pregnancy due
to retroperitoneal bleeding which increased the risk for
mortality for both patient and fetus.
Regarding the titer level and severity of bleeding, there
appeared to be a higher requirement for blood products,
worsening of bleeding diathesis, and, in some cases, worse
outcomes with a Bethesda titer >100 BU [4, 8, 9, 11]. In one
of the cases, the patient inhibitor level increased from the
initial level of 64 BU to a level as high as 132 BU. As previously mentioned, this patient died due to hemorrhagic
shock on postpartum day 8 [9]. Likewise, the case of acquired factor VIII concomitantly with SLE resulted in a
massive retroperitoneal bleed. This patient had an initial titer
of 614 BU; however, the patient was able to successfully clear
the inhibitor although she did have to terminate pregnancy
due to the risk of worsening complications if she continued
to term [11]. Moreover, Michiels et al. described a case of a
young woman who delivered a stillborn and subsequently
developed postpartum hemorrhage with titers as high as
625 BU [4]. This patient did not receive remission at followup visits 24 years later despite immunosuppressive therapy.
Lastly, Kotani et al. described a case of postpartum hemorrhage with an initial titer level of 458 BU. This patient
along with her neonate developed complications; however,
after the patient received several blood products including
nineteen packed red blood cells, ﬁfty-one units of fresh
frozen plasma, 4.8 mg of factor VIIa, and pulse steroid
therapy, the patient developed remission [8]. Previous
studies note that severity of bleeding does not correlate with
the titer level; however, our literature review shows that the
severity of bleeding is at least correlated with the titer level of
the inhibitor level which reaches as high as 100 BU.
Remission was achieved in most patients by a two-step
process aimed at controlling the bleeding and eliminating
the inhibitor. Our literature review showed that several
patients were treated with some combinations of either
desmopressin, factor eight inhibitor bypassing activity
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(FEIBA), recombinant human factor VIIa, or recombinant
porcine factor VIII concentrate, tranexamic acid, or some
other blood products including packed red blood cells or
fresh frozen plasma. Several agents were used for eradication
of the inhibitor including prednisone, methylprednisolone,
cyclophosphamide, rituximab, and azathioprine. The European Acquired Hemophilia Registry (EACH 2) reported
42 documented cases of acquired factor VIII deﬁciency
associated with the peripartum period out of the total 501
documented cases. Of the 42 cases, 74% of patients acquired
complete remission with ﬁrst-line immunosuppressive
treatment with all women being alive at the last follow-up
visit. To date, there has not been a registry developed in the
United States.

5. Learning Points
Acquired factor VIII hemophilia secondary to the coagulation factor inhibitor autoantibody is a rare condition that
can be associated with pregnancy and the peripartum period.
When it does occur during pregnancy, it most often occurs
postpartum but can rarely appear before delivery. The patients present with a large sweep of bleeding manifestations
that can pose diagnostic and management challenges. Elevated PTT that fails to correct by adding fresh plasma
suggests the presence of the inhibitor and should trigger
further workup. As cases are extremely rare, increased
awareness and further studies are needed so that prompt
intervention can be achieved.
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